Latest Immunosuppressive agents Stories
New data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis (RRMS) demonstrated a significant reduction in the mean number of gadolinium-enhancing (GdE) lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose.
Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced today that patients are being enrolled for the BRAVO Phase III pivotal trial.
Tomorrow's issue of the scientific journal The Lancet, Volume 371, Issue 9630, includes an article covering Active Biotech's (OMX Nordic: ACTI) and Teva Pharmaceutical Industries Ltd's novel oral MS drug laquinimod.
In patients with rheumatoid arthritis, use of disease-modifying antirheumatic drugs, or DMARDs, seems to lower the increased risk of cardiovascular disease associated with rheumatoid arthritis, research suggests.
A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday.
Patients with rheumatoid arthritis who are treated with low-dose prednisone have an increased risk of coming down with pneumonia, a new study indicates.
NEW YORK (Reuters Health) - Even if an initial course of methotrexate for the treatment of rheumatoid arthritis (RA) gives disappointing results, persistence may pay off. A second course may be more successful, researchers report.
NEW YORK (Reuters Health) - While pimecrolimus cream can be very effective for treating atopic dermatitis (often called eczema), there has been concern about infections because it is an immune suppressing drug -- but that seems to be unfounded.
- Withering but not falling off, as a blossom that persists on a twig after flowering.